文献速递前列腺癌前列腺增生与排尿功能障碍

钬激光前列腺剜除术后偶发前列腺癌诊断常见

Incidental Prostate Cancer Diagnosis Is Common After Holmium Laser Enucleation of the Prostate.
PubMed 文献 · Urology · 2023-12-01

该研究纳入2018至2022年连续接受钬激光前列腺剜除术(HoLEP)的913例患者,其中183例(20%)术后病理诊断为偶发前列腺癌(iPCa)。多因素分析显示前列腺特异性抗原密度(OR 1.06)、术前活检状态(OR 0.47)和当前使用5α还原酶抑制剂(OR 0.64)与iPCa诊断相关。作者建议开发标准化的风险适配评估,扩大影像学使用和选择性活检,以在非肿瘤手术前优先识别临床显著前列腺癌。

要点

  • 913例HoLEP患者中183例(20%)诊断为偶发前列腺癌。
  • PSA密度(OR 1.06)、术前活检状态(OR 0.47)和当前5α还原酶抑制剂使用(OR 0.64)与iPCa诊断相关。
  • 作者建议开发标准化风险适配评估,扩大影像学使用和选择性活检。

核心结论

  • 在显著预筛查人群中,HoLEP术后iPCa发生率为20%。
  • 与iPCa诊断相关的术前特征包括年龄增加、PSA密度增加和当前使用5α还原酶抑制剂。
  • 这些因素单独用于前瞻性识别iPCa高风险患者的临床效用可能有限。
  • 作者建议并倡导开发标准化的风险适配评估,重点扩大影像学使用和选择性活检,以在非肿瘤手术前优先识别临床显著前列腺癌。

研究设计与样本

  • 研究纳入2018年至2022年连续接受HoLEP的患者,从前瞻性维护的数据库中提取全面临床数据。
  • iPCa定义为HoLEP标本病理检查诊断前列腺癌。
  • 比较有和无iPCa患者的术前临床变量。

主要发现

  • 913例HoLEP患者中,183例(20%)诊断为iPCa。
  • 大多数患者(95%)有术前前列腺特异性抗原(PSA),9%有阴性MRI,30%有阴性前列腺活检。
  • 多因素分析显示,PSA密度(OR 1.06;95%CI 1.03,1.10;P<.001)、术前活检状态(OR 0.47;95%CI 0.30,0.75;P=.002)和当前使用5α还原酶抑制剂(OR 0.64;95%CI 0.43,0.97;P=.034)与iPCa诊断相关。

临床怎么用

  • 作者建议并倡导开发标准化的风险适配评估,重点扩大影像学使用和选择性活检,以在非肿瘤手术前优先识别临床显著前列腺癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the incidence of incidental prostate cancer detection (iPCa) after holmium laser enucleation of the prostate (HoLEP). The published rate of iPCa after HoLEP is widely variable from 7% to 23% and we aim to define preoperative risk factors for iPCa to inform risk-adjusted preoperative evaluation for PCa. METHODS: Consecutive patients undergoing HoLEP from 2018 to 2022 were included and comprehensive clinical data abstracted from a prospectively maintained database. iPCa was defined as a diagnosis of PCa on pathologic examination of the HoLEP specimen. Patients with and without iPCa were compared with respect to preoperative clinical variables. RESULTS: Of 913 HoLEP patients, 183 (20%) were diagnosed with iPCa. Most patients (95%) had a preoperative prostate-specific antigen (PSA), 9% had negative MRI, and 30% had negative prostate biopsy. On multivariable analysis, PSA density (OR 1.06; 95% CI 1.03, 1.10; P < .001), preoperative biopsy status (OR 0.47, CI 0.30, 0.75; P = .002), and current 5-alpha reductase inhibitor use (OR 0.64, CI 0.43, 0.97; P = .034), were associated with iPCa diagnosis. CONCLUSION: In a significantly prescreened population, we identified a 20% rate of iPCa after HoLEP. Preoperative characteristics associated with iPCa diagnosis included increasing age, increasing PSA density, and current 5-alpha reductase inhibitor use. However, these factors alone may be of limited clinical utility to prospectively identify patients at high risk of iPCa diagnosis. We suggest and advocate for development of a standardized, risk-adapted evaluation focused on expanded use of imaging and selective biopsy to prioritize identification of clinically significant PCa prior to nononcologic surgery.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Sakai A, Borza T, Antar A, et al. Incidental Prostate Cancer Diagnosis Is Common After Holmium Laser Enucleation of the Prostate. Urology. 2023. PMID: 38043905. doi:10.1016/j.urology.2023.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。